Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Liquidia Technologies ( (LQDA) ) has provided an announcement.
On May 23, 2025, Liquidia Corporation announced that its product YUTREPIA received final FDA approval for treating PAH and PH-ILD. The approval follows the expiration of exclusivity rights held by United Therapeutics, which had delayed YUTREPIA’s approval. Despite this milestone, ongoing and potential litigation could impact the product’s commercialization. Liquidia plans to begin marketing YUTREPIA immediately, emphasizing its ease of use and effectiveness demonstrated in clinical trials. The approval is expected to provide a new treatment option for patients, although legal challenges from United Therapeutics may pose obstacles.
The most recent analyst rating on (LQDA) stock is a Buy with a $22.00 price target. To see the full list of analyst forecasts on Liquidia Technologies stock, see the LQDA Stock Forecast page.
Spark’s Take on LQDA Stock
According to Spark, TipRanks’ AI Analyst, LQDA is a Neutral.
Liquidia Technologies’ overall stock score reflects its financial struggles, with high leverage and consistent losses posing significant risks. While there is positive stock momentum and strategic preparations for YUTREPIA’s launch, the recent lawsuit and unprofitability weigh heavily on its valuation. Investors should be cautious, considering the mixed financial outlook and potential legal hurdles.
To see Spark’s full report on LQDA stock, click here.
More about Liquidia Technologies
Liquidia Corporation is a biopharmaceutical company focused on developing innovative therapies for patients with rare cardiopulmonary diseases. The company’s primary product, YUTREPIA, is a prostacyclin analog inhalation powder designed to treat pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). Liquidia utilizes its proprietary PRINT technology to enhance drug delivery.
Average Trading Volume: 1,272,799
Technical Sentiment Signal: Buy
Current Market Cap: $1.33B
See more data about LQDA stock on TipRanks’ Stock Analysis page.